Heartflow (NASDAQ:HTFL) Major Shareholder Bain Capital Life Sciences Inv Sells 254,110 Shares

Heartflow, Inc. (NASDAQ:HTFL) major shareholder Bain Capital Life Sciences Inv sold 254,110 shares of the business’s stock in a transaction on Tuesday, April 28th. The shares were sold at an average price of $30.51, for a total transaction of $7,752,896.10. Following the sale, the insider directly owned 10,194,048 shares in the company, valued at $311,020,404.48. This trade represents a 2.43% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this link. Large shareholders that own more than 10% of a company’s stock are required to disclose their sales and purchases with the SEC.

Bain Capital Life Sciences Inv also recently made the following trade(s):

• On Thursday, April 30th, Bain Capital Life Sciences Inv sold 948,757 shares of Heartflow stock. The shares were sold at an average price of $29.23, for a total transaction of $27,732,167.11.
• On Wednesday, April 29th, Bain Capital Life Sciences Inv sold 797,133 shares of Heartflow stock. The shares were sold at an average price of $29.37, for a total transaction of $23,411,796.21.
• On Wednesday, February 4th, Bain Capital Life Sciences Inv sold 2,000,000 shares of Heartflow stock. The shares were sold at an average price of $28.05, for a total transaction of $56,100,000.00.

Heartflow Price Performance

Shares of HTFL opened at $29.76 on Friday. The firm has a market capitalization of $2.55 billion and a PE ratio of -14.95. Heartflow, Inc. has a 1-year low of $20.13 and a 1-year high of $41.22. The company’s fifty day moving average price is $26.11 and its 200-day moving average price is $29.28.

Institutional Investors Weigh In On Heartflow

Hedge funds have recently added to or reduced their stakes in the business. Caitong International Asset Management Co. Ltd purchased a new stake in Heartflow in the fourth quarter valued at $27,000. TFC Financial Management Inc. purchased a new stake in shares of Heartflow during the 3rd quarter worth about $40,000. Russell Investments Group Ltd. purchased a new stake in shares of Heartflow during the 4th quarter worth about $45,000. Legal & General Group Plc acquired a new position in shares of Heartflow during the 3rd quarter worth about $59,000. Finally, Strs Ohio acquired a new position in shares of Heartflow during the 4th quarter worth about $99,000.

Analyst Ratings Changes

Several research firms have commented on HTFL. Canaccord Genuity Group upped their price target on shares of Heartflow from $40.00 to $43.00 and gave the company a “buy” rating in a report on Thursday, March 19th. JPMorgan Chase & Co. lowered their price target on shares of Heartflow from $40.00 to $35.00 and set an “overweight” rating on the stock in a report on Thursday, March 19th. Finally, Wells Fargo & Company lowered their price target on shares of Heartflow from $38.00 to $35.00 and set an “overweight” rating on the stock in a report on Thursday, March 19th. Five equities research analysts have rated the stock with a Buy rating, two have issued a Hold rating and one has issued a Sell rating to the company’s stock. According to data from MarketBeat.com, the company presently has an average rating of “Moderate Buy” and a consensus price target of $37.67.

Heartflow Company Profile

HeartFlow, Inc (NASDAQ: HTFL) is a medical technology company that develops non-invasive diagnostic solutions for coronary artery disease. The company’s core offering translates coronary CT angiography (CTA) data into a patient-specific, three-dimensional physiological model of the coronary arteries. Using advanced image processing and computational modeling, HeartFlow’s analysis estimates fractional flow reserve (FFR) values throughout the coronary tree to identify ischemia-producing lesions without the need for invasive pressure-wire measurements.

HeartFlow’s cloud-based service integrates with clinical workflows: clinicians submit coronary CTA images and receive a detailed, color-coded 3D map and report that highlights lesion-specific FFR values and physiological impact.